Nuevos hipolipidemiantes
EMC - Tratado de Medicina, ISSN: 1636-5410
2021
- 2Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures2
- Readers2
Review Description
El tratamiento con estatinas sigue siendo la piedra angular del tratamiento de la hipercolesterolemia, y a menudo requiere la asociación de ezetimiba para alcanzar los objetivos recomendados de colesterol de lipoproteínas de baja densidad (LDL). Sin embargo, a pesar del tratamiento con una estatina en la dosis máxima tolerada en combinación con ezetimiba, muchos pacientes no alcanzan los objetivos de colesterol-LDL y existen otros tratamientos como los inhibidores de PCSK9 (anticuerpos monoclonales ya disponibles e inclisirán, en desarrollo) y el ácido bempedoico. Se están desarrollando algunos tratamientos específicos para la hipercolesterolemia familiar homocigótica (como el evinacumab). Además de actuar sobre el colesterol-LDL, otras estrategias terapéuticas permiten reducir las lipoproteínas ricas en triglicéridos: el ácido eicosapentaenoico y el pemafibrato están en desarrollo. Los nuevos enfoques terapéuticos también ofrecen esperanzas para reducir las concentraciones de lipoproteína (a). Por otro lado, las estrategias dirigidas a actuar sobre las HDL (lipoproteínas de alta densidad) siguen siendo más inciertas. El reto para el futuro será determinar cómo elegir entre las distintas posibilidades de asociaciones terapéuticas de agentes hipolipidemiantes en función del tipo de anomalía lipídica y de las características clínicas del paciente.
Bibliographic Details
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know